Vraylar (brand name) is another prescription drug that is used to treat schizophrenia and symptoms associated with some kinds of bipolar disorder, particularly bipolar 1 disorder. Additionally, this drug is also prescribed alongside antidepressant medications to treat major depressive disorder (MDD), a mood disorder that results in persistent feelings of sadness and lack of interest. The active ingredient in the drug is cariprazine. Like lumateperone, cariprazine is an atypical antipsychotic and is only available under the brand name.
The boxed warnings of Vraylar are very similar to that of Caplyta — suicidal thoughts and behaviors in young adults and children and increased risk of death in older people with dementia psychosis. Common side effects include slow movements, difficulty moving, tremors, uncontrolled body movements (tardive dyskinesia or TD), restlessness, sleepiness, trouble sleeping, nausea, vomiting, indigestion, constipation, fatigue, increased appetite, and dizziness. The drug also poses a risk of stroke, NMS, problems with your metabolism characterized by high blood sugar, increased cholesterol and triglycerides in your system, and weight gain. Difficulty swallowing, increased risk of falls and injuries, low white blood cell count, seizures, and an increase in body temperature are additions to the drug’s list of serious side effects.
Like Caplyta, Vraylar could also cause allergic reactions in some people who might be sensitive to some or all of the ingredients in the capsule. Apart from cariprazine, Vraylar contains gelatin, magnesium stearate, pregelatinized starch, titanium dioxide, and other colorants.